Lecanemab (Lequembi, Esai), an amyloid beta–directed antibody therapy, is approved by the US Food and Drug Administration (FDA) for the treatment of Alzheimer's disease (AD). But exactly how the drug ...

For over thirty years, researchers have primarily studied the accumulation of amyloid beta proteins in the brains of Alzheimer’s patients. They also focus on how that component negatively impacts ...

A main theory behind the cause of Alzheimer’s disease is the build-up of the protein amyloid-beta in the brain. Researchers from the University of Cincinnati provide evidence suggesting it’s the ...

CHAPEL HILL, N.C. (WTVD) -- A research team at UNC is studying how amyloid plaque forms in the brain of Alzheimer's patients in hopes of developing breakthrough treatments for the disease. "When we ...

Scientists have developed a promising new approach to treating Alzheimer’s disease by turning ordinary brain cells into powerful plaque-clearing machines. Instead of requiring frequent antibody ...

A longitudinal cohort study showed that a higher amyloid-beta (Aβ) load in centenarians was associated with poorer cognitive performance, particularly executive functioning. Two thirds of centenarians ...

By watching Alzheimer’s-related protein clumping unfold second by second, researchers have uncovered new clues about the role of metal ions.

At least 55 million people are living with dementia worldwide. Among the various forms of dementia, Alzheimer’s disease — a neurodegenerative disorder that is caused by a loss of neurons — is the most ...